Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in lactotrophs | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 189 | 0.74 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 5521
Sealed predictions
- MYT1L in dopamine neurons, braak+0.43 (p 0.251) → -0.23 (p 0.560)receipt 5528
Swarm cases
receipt 5528: MYT1L in dopamine neurons, braak
- power
- full sample +0.07 (p 0.774, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.08 (p 0.741, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.424, n 18). could be the mix.
- skeptic
- leave-one-out range -0.03 to +0.21, sign flips 1; without severely affected donors +0.07 (p 0.774, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MYT1L in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts